Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDNA NASDAQ:NTRA NYSE:NVTA NASDAQ:RDNT NASDAQ:VCYT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDNACareDx$23.37+2.7%$20.44$10.96▼$24.02$1.21B2.49710,535 shs361,661 shsNTRANatera$216.42-2.9%$205.34$131.81▼$256.36$30.99B1.561.32 million shs668,159 shsNVTAInvitae$0.00$0.00$0.02▼$0.02$80K1.5923.72 million shsN/ARDNTRadNet$58.13+3.5%$55.72$50.76▼$85.84$4.57B1.41803,896 shs424,856 shsVCYTVeracyte$48.49-1.5%$38.47$22.61▼$50.71$3.87B1.98959,090 shs867,340 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDNACareDx+3.64%+3.08%+4.26%+32.65%+15.37%NTRANatera+4.38%+4.58%+14.71%+13.33%+35.71%NVTAInvitae0.00%0.00%0.00%0.00%0.00%RDNTRadNet+3.73%+3.44%-3.45%-8.20%-4.89%VCYTVeracyte+4.17%+3.01%+21.82%+51.69%+76.80%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDNACareDx$23.37+2.7%$20.44$10.96▼$24.02$1.21B2.49710,535 shs361,661 shsNTRANatera$216.42-2.9%$205.34$131.81▼$256.36$30.99B1.561.32 million shs668,159 shsNVTAInvitae$0.00$0.00$0.02▼$0.02$80K1.5923.72 million shsN/ARDNTRadNet$58.13+3.5%$55.72$50.76▼$85.84$4.57B1.41803,896 shs424,856 shsVCYTVeracyte$48.49-1.5%$38.47$22.61▼$50.71$3.87B1.98959,090 shs867,340 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDNACareDx+3.64%+3.08%+4.26%+32.65%+15.37%NTRANatera+4.38%+4.58%+14.71%+13.33%+35.71%NVTAInvitae0.00%0.00%0.00%0.00%0.00%RDNTRadNet+3.73%+3.44%-3.45%-8.20%-4.89%VCYTVeracyte+4.17%+3.01%+21.82%+51.69%+76.80%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDNACareDx 2.00Hold$25.007.00% UpsideNTRANatera 2.81Moderate Buy$256.1218.34% UpsideNVTAInvitae 0.00N/AN/AN/ARDNTRadNet 2.90Moderate Buy$87.4350.40% UpsideVCYTVeracyte 2.56Moderate Buy$47.57-1.89% DownsideCurrent Analyst Ratings BreakdownLatest NVTA, VCYT, NTRA, CDNA, and RDNT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/5/2026NTRANatera The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy ➝ Neutral$245.006/5/2026NTRANatera The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy ➝ Neutral$245.006/2/2026NTRANatera Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$260.006/2/2026VCYTVeracyte Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$55.006/1/2026VCYTVeracyte Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$48.00 ➝ $57.006/1/2026NTRANatera Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy6/1/2026VCYTVeracyte Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/28/2026VCYTVeracyte Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$48.005/27/2026CDNACareDx Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)5/20/2026RDNTRadNet BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$70.00 ➝ $65.005/12/2026RDNTRadNet Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)(Data available from 6/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDNACareDx$379.80M3.18$0.01 per share3,369.98$5.89 per share3.97NTRANatera$2.31B13.44N/AN/A$12.38 per share17.48NVTAInvitae$481.58M0.00N/AN/A$0.42 per share0.00RDNTRadNet$2.04B2.24$3.46 per share16.80$17.58 per share3.31VCYTVeracyte$517.15M7.48$1.53 per share31.74$16.57 per share2.93Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDNACareDx-$21.35M-$0.16N/A77.88N/A-2.01%-2.65%-1.96%8/5/2026 (Estimated)NTRANatera-$208.16M-$1.63N/AN/AN/A-9.05%-14.74%-10.27%8/6/2026 (Estimated)NVTAInvitae-$3.11B-$5.38N/AN/AN/A-299.14%-6,100.71%-19.68%N/ARDNTRadNet-$18.65M-$0.18N/A58.13N/A-0.66%2.77%0.97%8/10/2026 (Estimated)VCYTVeracyte$66.35M$1.0944.4733.91N/A16.25%9.07%8.38%8/5/2026 (Estimated)Latest NVTA, VCYT, NTRA, CDNA, and RDNT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026RDNTRadNet-$0.14-$0.28-$0.14-$0.43$557.93 million$575.63 million5/5/2026Q1 2026VCYTVeracyte$0.34$0.52+$0.18$0.35$130.36 million$139.07 million4/28/2026Q1 2026CDNACareDx$0.11$0.34+$0.23$0.05$102.03 million$117.70 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCDNACareDxN/AN/AN/AN/AN/ANTRANateraN/AN/AN/AN/AN/ANVTAInvitaeN/AN/AN/AN/AN/ARDNTRadNetN/AN/AN/AN/AN/AVCYTVeracyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDNACareDxN/A3.403.07NTRANateraN/A2.962.83NVTAInvitaeN/A2.392.25RDNTRadNet0.791.171.17VCYTVeracyteN/A9.318.92Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDNACareDxN/ANTRANatera99.90%NVTAInvitae61.28%RDNTRadNet77.90%VCYTVeracyteN/AInsider OwnershipCompanyInsider OwnershipCDNACareDx2.40%NTRANatera5.05%NVTAInvitae0.74%RDNTRadNet5.60%VCYTVeracyte1.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDNACareDx74051.66 million50.42 millionOptionableNTRANatera6,140143.21 million135.98 millionOptionableNVTAInvitae1,700267.01 million284.37 millionNo DataRDNTRadNet11,26478.63 million74.23 millionOptionableVCYTVeracyte79079.79 million78.68 millionOptionableNVTA, VCYT, NTRA, CDNA, and RDNT HeadlinesRecent News About These CompaniesVeracyte, Inc. $VCYT Shares Sold by GW&K Investment Management LLCJune 10 at 6:53 AM | marketbeat.comVeracyte, Inc. $VCYT Shares Sold by Amova Asset Management Americas Inc.June 10 at 3:08 AM | marketbeat.comHere's Why Veracyte (VCYT) is a Strong Growth StockJune 9 at 10:46 AM | zacks.comVeracyte, Inc. (NASDAQ:VCYT) Receives Consensus Rating of "Moderate Buy" from AnalystsJune 8 at 2:22 AM | americanbankingnews.comVeracyte, Inc. (NASDAQ:VCYT) Receives Average Rating of "Moderate Buy" from BrokeragesJune 8 at 2:21 AM | marketbeat.comBNP Paribas Financial Markets Buys 281,079 Shares of Veracyte, Inc. $VCYTJune 7 at 3:22 AM | marketbeat.comMarc Stapley Sells 138,051 Shares of Veracyte (NASDAQ:VCYT) StockJune 6, 2026 | americanbankingnews.comInsider Selling: Veracyte (NASDAQ:VCYT) EVP Sells 3,176 Shares of StockJune 5, 2026 | insidertrades.comVeracyte (NASDAQ:VCYT) EVP Annie Mcguire Sells 3,176 SharesJune 4, 2026 | marketbeat.comVeracyte (NASDAQ:VCYT) CFO Sells $177,088.53 in StockJune 4, 2026 | marketbeat.comVeracyte (NASDAQ:VCYT) Insider John Leite Sells 13,975 SharesJune 4, 2026 | marketbeat.comInsider Selling: Veracyte (NASDAQ:VCYT) CEO Sells 138,051 Shares of StockJune 4, 2026 | marketbeat.comHow Veracyte (VCYT) Investors Can Read The Latest Unchanged Analyst CallJune 4, 2026 | finance.yahoo.comWhy Is Veracyte (VCYT) Up 18.2% Since Last Earnings Report?June 4, 2026 | zacks.comVeracyte, Inc. (VCYT) Discusses ASCO Findings From OPTIMA and ENZAMET Phase III Trials in Breast and Prostate Cancer - SlideshowJune 3, 2026 | seekingalpha.comCanaccord Genuity Reaffirms Their Hold Rating on Veracyte (VCYT)June 3, 2026 | theglobeandmail.comVeracyte, Inc. (VCYT) Presents at 46th Annual William Blair Growth Stock Conference - SlideshowJune 3, 2026 | seekingalpha.comVeracyte (NASDAQ:VCYT) Upgraded to "Strong-Buy" at Wolfe ResearchJune 3, 2026 | marketbeat.comVeracyte (NASDAQ:VCYT) Now Covered by Analysts at Wolfe ResearchJune 2, 2026 | marketbeat.comVeracyte, Inc. (VCYT) Discusses ASCO Findings From OPTIMA and ENZAMET Phase III Trials in Breast and Prostate Cancer TranscriptJune 1, 2026 | seekingalpha.comVeracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.June 1, 2026 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesRocket Lab Just Hit a New All-Time High—Time to Buy or Let It Breathe?By Ryan Hasson | May 12, 2026Is Everspin Technologies the Next AI Edge Breakout?By Thomas Hughes | May 18, 20263 AI Data Center Stocks Worth Watching for Capital RotationBy Ryan Hasson | May 15, 2026Rocket Lab Keeps Making Headlines and Highs—Here's What's Driving the Latest MoveBy Ryan Hasson | May 27, 2026Why Satellogic Could Be One of the Biggest Space Winners of 2026By Thomas Hughes | May 14, 2026NVTA, VCYT, NTRA, CDNA, and RDNT Company DescriptionsCareDx NASDAQ:CDNA$23.36 +0.62 (+2.70%) As of 03:33 PM Eastern This is a fair market value price provided by Massive. Learn more.CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.Natera NASDAQ:NTRA$216.42 -6.40 (-2.87%) As of 03:33 PM Eastern This is a fair market value price provided by Massive. Learn more.Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.Invitae NYSE:NVTAInvitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.RadNet NASDAQ:RDNT$58.13 +1.95 (+3.47%) As of 03:33 PM Eastern This is a fair market value price provided by Massive. Learn more.RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.Veracyte NASDAQ:VCYT$48.49 -0.75 (-1.52%) As of 03:33 PM Eastern This is a fair market value price provided by Massive. Learn more.Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Chewy’s Growth Engine Is Stronger Than the Market Thinks FuelCell Energy Just Got a Wake-Up Call From Wall Street Uranium Energy Corp Melts Down—Nuclear Opportunity at Hand Corning Is Paving AI's Future With Glass Short Sellers Are Piling Into Wingstop, But Analysts See Big Upside Optical Cable Corporation: Strong Earnings, But Hurdles Remain The J.M. Smucker Company’s Dividend: Too Sweet to Ignore? Why's Amazon Suddenly Lagging the S&P 500, and Is It a Warning? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
